Skip to main content

Table 1 Pharmacokinetic parameters of VCE-003.2. Pharmacokinetic parameters of VCE-003.2 in plasma following a single intravenous (i.v.) (10 mg/kg) and oral (50 mg/kg) dose in Sprague Dawley rats

From: Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration

Compound

Route

Cmax (ng/mL)

Tmax (h)

AUCt ng/mL*h)

Bioavailability

Brain Concentration (24 h) (ng/mL)

VCE-003.2

IV

83160

0.08

475094.96

 

93.7 ± 37.7

VCE-003.2

ORAL

20266.67

8

327154.14

13.77%

86.8 ± 34.0